recombinant ndv vectored vaccine for sars-cov-2
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 20, 2021 (NCT04871737)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05710783 | Phase 2/Phase 3 (Phase 3) | Nov 9, 2022 | Government of Mexico, Instituto Nacional de Enfermedades Respiratorias, Laboratorio Avi-Mex, S.A. de C.V. |
| NCT05205746 | Phase 2 | Nov 23, 2021 | Government of Mexico, Instituto Nacional de Enfermedades Respiratorias, Laboratorio Avi-Mex, S.A. de C.V., Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro Social |
| NCT04871737 | Phase 1 | May 20, 2021 | Agencia Mexicana de Cooperación Internacional para el Desarrollo. AMEXID, Government of Mexico, Laboratorio Avi-Mex, S.A. de C.V., National Autonomous University of Mexico |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Mexico | Government | 3 | 0 | 3 | 2021 |
| Laboratorio Avi-Mex, S.A. de C.V. | For profit | 3 | 3 | 3 | 2021 |
| Instituto Nacional de Enfermedades Respiratorias | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Agencia Mexicana de Cooperación Internacional para el Desarrollo. AMEXID | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Autonomous University of Mexico | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro Social | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1